Dr. Reddy's Laboratories Ltd. News and Updates

Name: Latest research reports of Dr. Reddy's Laboratories Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Dr. Reddy's Laboratories Ltd.
Rating: 1
Author: Deven Choksey

Keep track of all breaking news on Dr. Reddy's Laboratories Ltd. from all sources in a single place.

Dr. Reddy's Laboratories Ltd.

11 Sep 2025, 12:31PM

1303.10

-0.08%

Dr Reddy's signs pact with J&J to acquire vertigo treatment brand

Business Standard

Dr Reddy's Laboratories on Thursday announced the completion of a definitive transaction with Johnson & Johnson to acquire Stugeron brand across the EMEA regions, with India and Vietnam as key markets. Stugeron contains Cinnarizine, an antihistamine indicated for the treatment of vestibular disturbances and vertigo. The acquisition presents a strategic opportunity for the Hyderabad-based drug firm to expand its footprint in the anti-vertigo space as well as strengthen its Central Nervous System (CNS) portfolio, Dr Reddy's Laboratories said in a statement. Dr Reddy's acquisition of the brand reflects a steady advancement in the company's efforts to expand into the anti-vertigo therapeutic segment, contributing to the continued development of CNS portfolio, said MV Ramana, CEO, Branded Markets (India and Emerging Markets), Dr Reddy's Laboratories. "Backed by our strong market access, we intend to extend the reach of Stugeron and its associated products across 18 key markets in the ..

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr Reddy's enters anti-vertigo segment with acquisition of Stugeron from Johnson & Johnson

Business Line | 11 Sep 2025, 10:57AM 1 more

Dr. Reddy's Laboratories Ltd.

11 Sep 2025, 12:00AM

1303.10

-0.08%

Stock Flash

Sell: Dr. Reddy's Laboratories Ltd.

Deven Choksey

Dr. Reddy’s Laboratories Ltd. has entered into a definitive agreement with Janssen Pharmaceutica NV, an affiliate of Johnson & Johnson, to acquire the STUGERON® brand along with its leading local brands STUGERON® FORTE and STUGERON® PLUS.

Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.

Dr. Reddy's Laboratories Ltd.

26 Aug 2025

1303.10

-0.08%

Dr Reddy's hopes GST reforms will fix pharma tax issues, boost access

Business Standard

Dr Reddy's Laboratories on Tuesday expressed hope that the new GST structure will take care of existing challenges and aid in ushering a rationalised, industry-friendly tax framework for the pharmaceutical industry. For an extended period, the pharmaceutical sector has faced structural challenges, including higher GST rates and an inverted duty structure, which have impacted the cost efficiency of domestic manufacturing and the affordability of medicines, Dr Reddy's Laboratories Chairman Satish Reddy said in a statement. "We are optimistic that the forthcoming reforms will address these critical concerns and introduce a rationalised, industry-friendly tax framework," he noted. Such measures will significantly improve the affordability and accessibility of essential medicines for every citizen, while also enhancing the global competitiveness and innovation capacity of the Indian pharmaceutical industry, Reddy said. The industry remains fully committed to working in close partnership

Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.

Dr Reddy's launches drug for treatment of chronic constipation

Business Line | 26 Aug 2025 1 more

Dr. Reddy's Laboratories Ltd.

04 Aug 2025

1303.10

-0.08%

Dr. Reddy's Laboratories Price Target Cut By Citi Over Intensifying Generic Competition Full Details

NDTV Profit

Citi notes that market expectations for Dr. Reddy's Semaglutide opportunity may be too optimistic.

Number of FII/FPI investors increased from 911 to 917 in Jun 2025 qtr.

Dr. Reddy's Laboratories Ltd.

29 Jul 2025

1303.10

-0.08%

Price Erosion across the US portfolio to remain the key overhang for its overall business

Sell: Dr. Reddy's Laboratories Ltd.

Deven Choksey

Revenue: For Q1FY26, the revenue increased by 11.4% YoY (+0.5% QoQ) to INR 85,721 Mn, below our estimates by 3.0%, led by weakness in North America, which was partially offset by higher momentum across Europe and the Emerging markets.

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

26 Jul 2025

1303.10

-0.08%

Dr Reddy's Laboratories invests 565 crore in Russian arm

Business Line

The transaction was the result of a decision to infuse up to 600 crore in the Russianarm taken by the board of the Hyderabad-based company in November 2024

Dr. Reddy's Laboratories Ltd. is trading above all available SMAs

Dr. Reddy's Laboratories Ltd.

24 Jul 2025

1303.10

-0.08%

Q1 miss for Dr Reddy's, but analysts remain hopeful for future prospects

Business Standard

Despite missing Q1 expectations, Dr Reddy's continues to see growth in key markets like Europe and India, while managing costs to offset challenges in the US

Number of FII/FPI investors increased from 911 to 917 in Jun 2025 qtr.

Dr. Reddy's Laboratories Ltd.

24 Jul 2025

1303.10

-0.08%

Dr. Reddy's Shares Spike After Morgan Stanley, BofA Raises Price Target Post Q1 Results

NDTV Profit

The company posted a consolidated net profit of Rs 1,418 crore for the AprilJune period, up just 1.8% year-on-year and below the Rs 1,514 crore consensus estimate.

Dr. Reddy's Laborato.. has an average target of 1278.56 from 9 brokers.

Dr. Reddy's Q1 Results Review: Systematix Maintains 'Hold' Rating On Weak U.S. Performance

NDTV Profit | 24 Jul 2025 9 more

Dr. Reddy's Laboratories Ltd.

24 Jul 2025

1303.10

-0.08%

Dr. Reddy's Laboratories (DRRD IN) Q1FY26 Result Update ...

Sell: Dr. Reddy's Laboratories Ltd.

Target

Prabhudas Lilladhar

Dr. Reddy's (DRRD) Q1FY26 EBITDA adjusted for licensing income was in line with our estimate. The base business margins and US sales ex of gRevlimid continued to remain weak. We have scale up base business margins from the current level of 15-16% to +21-22% in FY27E. Our FY26 and FY27E EPS broadly remain unchanged. DRRD have been investing cash flow from gRevlimid to build pipeline across peptides, biosimilars and GLP products; benefits of that may take some time. Further thin US pipeline in near term and competition in...